Focus on Alectinib and Competitor Compounds for Second Line Therapy in ALK Rearranged NSCLC

by Samuel J Klempner, Samuel J Klempner, Phu Tran
Published 2016-11-01

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma

by Dan Zhao, Samuel J. Klempner, Joseph Chao
Published 2019-05-01

Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?

by Phu Tran, Cham Nguyen, Samuel J. Klempner
Published 2016-11-01

A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling

by Joseph Chao, Jeeyun Lee, Kyung Kim, So Young Kang, Taehyang Lee, Kyoung-Mee Kim, Seung Tae Kim, Samuel J. Klempner, Samuel J. Klempner, Hyuk Lee
Published 2020-02-01

The impact of gender, race, socioeconomic status, and treatment on outcomes in esophageal cancer: A population-based analysis

by Phu N Tran, Thomas H Taylor, Samuel J Klempner, Jason A Zell
Published 2017-01-01

Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors

by Jonathan W. Riess, Shaila Rahman, Waleed Kian, Claire Edgerly, Andreas M. Heilmann, Russell Madison, Shakti H. Ramkissoon, Shai Shlomi Klaitman, Jon H. Chung, Sally E. Trabucco, Dexter X. Jin, Brian M. Alexander, Samuel J. Klempner, Lee A. Albacker, Garrett M. Frampton, Laila C. Roisman, Vincent A. Miller, Jeffrey S. Ross, Alexa B. Schrock, Jeffrey P. Gregg, Nir Peled, Ethan S. Sokol, Siraj M. Ali
Published 2021-10-01